by Teresa Carroll | News and Updates
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and... by Teresa Carroll | News and Updates
Erva Bayraktar, Ph.D. was recently awarded the Peripheral Nerve Society’s Laura Feltri Basic Science Fellowship at its annual meeting, held in May in Edinburgh, Scotland. This prestigious grant provides two years of funding to allow a junior scientist to... by Teresa Carroll | News and Updates
In a TIN-sponsored study newly published in the May issue of Neuromuscular Disorders (https://doi.org/10.1016/j.nmd.2025.105345) the Martini group now reports that CMT1X mice treated with Fingolimod showed improved nerve function, and the drug positively changed some... by Teresa Carroll | News and Updates
The sponsor of the study is NMD Pharma A/S. If you’re living with Charcot-Marie-Tooth (CMT) disease, specifically CMT1 or CMT2 subtypes you may be eligible to participate in an exciting new clinical trial. NMD Pharma, a biotechnology company, has received approval... by Teresa Carroll | News and Updates, Research
New Physical Exercise study published in November, 2024 issue of the Journal of the Peripheral Nervous System The results of a TIN-sponsored study to determine the effects of exercise on the progression of CMT1X, using a mouse model of CMT1X, was first published as... by Teresa Carroll | News and Updates
For Steve O’Donnell, founder of Therapies for Inherited Neuropathies, those are words to live by. He calls them his life’s slogan. The slogan helps him self-motivate to spread awareness of Charcot Marie Tooth disease and to raise money for CMT research. It’s guided... 
